氨磺必利治疗76例精神分裂症的临床研究

发布时间：2019-04-23 21:03

【摘要】：目的了解国产氨磺必利治疗精神分裂症的疗效及安全性。方法对76例精神分裂症患者分为国产氨磺必利片(研究组)或利培酮片(对照组)治疗,观察疗程为8周。于入组时及治疗后第2、4、6、8周末,采用阳性与阴性症状量表(PANSS)进行疗效评估。在治疗前和试验结束时,用不良反应症状量表(TESS)、心电图、血生化检查等进行安全性评估。结果研究组有效率为75.0%,对照组为72.5%,两组比较差异无统计学意义(P0.05)。PANSS评分显示,研究组阴性症状分比对照组减低更明显,差异有统计学意义(P0.05)。两组不良反应发生率差异无统计学意义(P0.05),氨磺必利导致体质量增加发生率更少。结论国产氨磺必利治疗精神分裂症的疗效与利培酮相当,对阴性症状疗效更明显,两药安全性较好。
[Abstract]:Objective to investigate the efficacy and safety of domestic sulfadipine in the treatment of schizophrenia. Methods 76 schizophrenic patients were divided into two groups: study group (study group) and risperidone tablet (control group). The course of treatment was 8 weeks. At the end of the 2nd, 4th, 6th and 8th week after treatment, positive and negative symptom scale (PANSS) was used to evaluate the curative effect. Before treatment and at the end of the trial, the safety was evaluated by (TESS), electrocardiogram and blood biochemical examination. Results the effective rate was 75.0% in the study group and 72.5% in the control group, and there was no significant difference between the two groups (P0.05). PANSS score showed that the negative symptom score in the study group was significantly lower than that in the control group. The difference was statistically significant (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05), and the incidence of body mass increase caused by sulfampicride was less. Conclusion the efficacy of domestic sulfadipine in the treatment of schizophrenia is similar to risperidone, especially in the treatment of negative symptoms, and the safety of the two drugs is better than that of risperidone in the treatment of schizophrenia.
【作者单位】：重庆市云阳县精神卫生保健院精神科;重庆市江北区精神卫生中心精神科;
【分类号】：R749.3

【参考文献】